

nDatalyze Corp.

CSE:NDAT OTC:NDATF

January 2024


Evidence-based, machine-learning-enhanced mental health
Clinical Decision Support System

Forward Looking Statements

Certain information set forth in this presentation contains “forward-looking information”, including “future-oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, the sale of the shares being offered hereunder; (iii) the expected development of the Company’s business, projects, and joint ventures; (iv) execution of the Company’s vision and growth strategy, including with respect to future M&A activity and global growth; (v) sources and availability of third-party financing for the Company’s projects; (vi) completion of the Company’s projects that are currently underway, in development or otherwise under consideration; (vi) renewal of the Company’s current customer, supplier and other material agreements; and (vii) future liquidity, working capital, and capital requirements. Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements. Although forward-looking statements contained in this presentation are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements

The Problem

Mental condition mis/over-diagnosis results in mis/overprescription leading to poor outcomes with the resultant feedback loop clogging the mental health system and lowering the overall quality of societal mental health. Here are example mis/overdiagnosis rates:



The Solution

YMI is a human/machine-learning hybrid Clinical Decision Support System (“CDSS”) designed to significantly lower mental condition mis/overdiagnosis & mis/overprescription rates of common mental conditions. The process involves using a proprietary Reference Database to establish a societal baseline for multiple mental conditions, thereafter determining an individual’s divergence from the baseline in order to predict probabilities of having, or developing, specified mental conditions. The proactive process is designed to identify potential developing conditions so they can be treated before they become debilitating. The process is patent-pending.



YMI combines:

to predict...

Memories

A Reference Database of objective, full life experiences of >1200 individuals from multiple age groups and ethnicities, including:

01

- Genetic expressions
- Childhood development
- Traumas & Allergies
- Doctor-diagnosed illnesses
- Physical conditions
- Lifestyle choices
- Brain wave (EEG) data (DNA snp data being studied now)

Highly-advanced, Predictive Psychiatric Assessment System

02


Uses AI/machine-learning guided by multiple highly-qualified Psychotherapists and data scientists. This allows the use of evidence-based data to predict an individual's current and future probabilities of multiple mental health conditions. This is designed to help increase the accuracy of mental condition diagnosis with the attendant benefits to societal mental health.

The Clinical Studies


03

The Company has launched two Clinical Studies designed to assess, calibrate and validate YMI. The Canadian Mental Health Association for process validation, and York University for DNA integration investigation.

Current Mental Condition Probabilities



...predicted trajectories for up to seven mental conditions.



Our Expert Guidance

We believe in empowering people with self-knowledge to better assess and address their mental health needs.

DR. KEITH COURTNEY



President,
Chief Psychiatric Officer

Keith is a double board-certified psychiatrist and a Clinical Assistant Professor at the University of Calgary and was a faculty member at the University of Vermont, Dartmouth Medical School, and the University of Nevada.

DR. CAROL MALEC



Ph.D, MSc, BScN

Carol has 22 years of private practice counselling experience and is a Certified Counsellor with Canadian Counselling and Psychotherapy Association (CCPA). She's also a guest lecturer at the University of Calgary.

DR. ANDREA PROTZNER



PhD, EEG Specialist

Andrea is an EEG specialist, a member of the Hotchkiss Brain Institute, and an Associate Professor at the University of Calgary. As the head of the University's Brain Dynamics Lab, she's researching the link between neural dynamics and cognition.

DR. KELTIE DUGGIN



M.D.

Keltie is a clinical lecturer at the University of Calgary and a hospitalist physician leader in the neurorehabilitation units at the Foothills Medical Centre and Vernon Fanning Centre.

JAMES DURWARD



Director,
Chief Technical Officer

James' expertise lies in data science and technical product experience, including image analysis, pattern recognition, and specialized databases.

Clinical Studies (two concurrent)

Highly-credible, third-party validation is imperative for market penetration

Study 1 - Canadian Mental Health Association – Clinical Study #1
Project Manager. PI's are Dr. Andrew Greenshaw, PhD, FRSA, Professor of Psychiatry and Neuroscience at the University of Alberta, and Dr. Bo Cao, Canada Research Chair in Computational Psychiatry and Associate Professor of Psychiatry at the University of Alberta.



Study 2 - York University Neuroscience, Dr. Dale Stevens, PhD,
DNA integration and validation, MITACS



Common Mental Health Assessments

Features		Ham-D (1)	BDI (2)	DSM Level 1 (3)	Clinician Visits (4)	Amen Clinics (5)
Anonymous	✓	✓	✓			
# Questions Analyzed	248	17	21	23	Many	Many
# Conditions Addressed	7	1	1	Multiple	Multiple	Multiple
Objective Data	✓			Some	Some	✓
Biometric Correlation	✓			Some	Some	✓
Brain Wave Correlation	✓					✓
Genetic Expressions	✓			✓	✓	✓
Family History	✓			✓	✓	✓
Childhood Development	✓			✓	✓	✓
Future Predictions	✓					
"What If" Capability	✓					?
Graphic Reports	✓					
Cost	\$	\$	\$	\$\$	\$\$\$	\$\$\$\$

Target Markets

- Primary Physicians (family doctors) (>500,000);
- Psychologists (> 120,000)
- Public/Private Health Insurers
- Liability insurers
- First Responders
- Law enforcement & Security

Corporate Management

Dr. Keith Courtney
President,
Chief Psychiatric Officer

Dr. Courtney is board-certified by the American Board of Psychiatry and Neurology, is a fellow of the American Society of Addictions Medicine . He also holds a certification in Ketamine-Assisted Psychotherapy from the Integrative Psychiatry Institute. His areas of interest include psychiatric assessment, psychopharmacology, psychedelic therapies and alternative psychiatric interventions.

Dusan Kuzma
MBA, MSc, Director

Experienced in product development and commercialization, Mr. Kuzma has served on the advisory board for advanced manufacturing technologies in Canada at the Information and Communications Technology Council.

James Durward
Chief Technical Officer
Director

A data scientist with over a decade of experience in image analysis, pattern recognition, and database development. He is a patented, published inventor with extensive public company experience.

Dwayne Vinck
CA, CFO

Mr. Vinck brings various business experiences, including financial reporting, directorships, executive leadership, change management, and project leadership. He also has experience in mergers and acquisitions and public company experience.

Steve Price
P.Eng, Director

With over 35 years of experience in engineering and management, including corporate operations, evaluations, and facilities design and operation, Mr. Price brings valuable expertise. He also has public company experience.

Gordon Crawford
P.Eng, Director


Mr. Crawford has over 30 years of engineering experience, including management roles in prestigious engineering firms. He was also a Co-Founding Partner and Vice President of a well-established mid-sized EPC engineering firm.

Share Metrics

(as of February 1, 2024)

CSE: NDAT OTC: NDATF

Market Cap	~C\$5M
Share Price	C\$0.13
Shares Outstanding	41 M
Management Ownership	~30%



nDatalyze
Corp.

CSE: NDAT
OTC: NDATF

Contact Us

Jim Durward, CEO/CTO

jimd@ndatalyze.com

(403) 689-3901

www.ndatalyze.com